Sumatriptan

Quick links to important sections

Sumatriptan

Selected form

Method of action: Analgesic, Antimigraine, Serotonergic

Treatment option: Migraine

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sumatriptan

Property Description
Active ingredient Sumatriptan Succinate
Form Tablet, Subcutaneous Injection, Nasal Spray
Pharmacological Class Triptan; Selective 5-HT1B/1D Receptor Agonist
General Purpose To address the acute, underlying causes of severe head pain episodes
Origin Synthetic Compound
Status Prescription-only medication (POM)

What Type of Medicine is Sumatriptan?

Sumatriptan is a synthetic pharmaceutical agent belonging to the specialized class of drugs known as Triptans, which are classified as selective serotonin receptor agonists. Sumatriptan holds a unique position as the first compound of the Triptan class to be approved, often serving as the benchmark for subsequent Triptans. It specifically acts as a highly selective agonist for the vascular 5-HT1B and 5-HT1D serotonin receptor subtypes. This targeted mechanism is clinically recognized for reversing the neurovascular processes associated with severe head pain, distinguishing it from general pain relievers.

Sumatriptan Composition and Available Forms

The essential active ingredient is Sumatriptan Succinate, an organic salt used to enhance the stability and absorption of the Sumatriptan molecule. The drug is notable for its flexibility in formulation, being readily available in several forms: the standard oral tablet, an aqueous solution for subcutaneous injection (parenteral administration), and a nasal spray. This diversity in administration route—oral, nasal, and injectable—is a distinguishing characteristic of the compound compared to other triptans, offering options for patients who may experience severe nausea.

General Purpose of Sumatriptan

The general purpose of Sumatriptan is to intervene directly in the acute phases of debilitating head pain by acting on the relevant vascular and neural components. It achieves this by stimulating targeted receptors, which results in the constriction of certain dilated cranial blood vessels and the inhibition of pro-inflammatory neurochemicals from nearby nerve terminals. This mechanism helps to normalize the enlarged blood vessels around the brain, relieving the associated pressure.

Regulatory References

  1. Sumatriptan - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Sumatriptan?

Possible Side Effects and Safety Information

The safety profile of Sumatriptan is defined by characteristic adverse reactions and critical constraints as documented in official government regulatory labeling. Adverse reactions are grouped by frequency and the body system affected, reflecting how regulatory bodies communicate risk.

Common Adverse Reactions

The most frequently reported side effects (classified as Common) often involve the Nervous System and General Disorders, and are typically transient. These include feelings of dizziness or drowsiness, flushing, and atypical sensations such as tingling, numbness, or a warm feeling. Sensations of tightness, pressure, or pain in the chest, throat, neck, or jaw are also common and are generally noted to be non-cardiac in origin. Nausea, vomiting, weakness, and fatigue are also frequently documented.

Serious Safety Concerns

Regulatory documents emphasize the risk of rare but serious vascular events. These documented Serious Adverse Reactions include major cardiovascular events such as myocardial infarction (heart attack), coronary artery vasospasm (Prinzmetal’s angina), and life-threatening arrhythmias. Cerebrovascular events, including stroke and cerebral hemorrhage, have also been officially reported. The potentially serious condition known as Serotonin Syndrome is listed as a risk, particularly when used with certain other medications.

Population-Specific Constraints

Official labeling defines several safety restrictions. Sumatriptan is contraindicated in patients with a history of ischemic heart disease, uncontrolled hypertension, stroke, or severe hepatic impairment (severe liver function reduction). Use is generally not recommended in the elderly (over 65 years) due to limited clinical experience. Furthermore, frequent, long-term use (e.g., ten or more days per month) is associated with the official risk of developing Medication Overuse Headache (MOH).

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Sumatriptan overdose outlines the potential for severe clinical outcomes and mandates immediate emergency actions. The primary documented manifestation of overdose is the exaggeration of known adverse events experienced during therapeutic use. These signs may include transient increases in blood pressure and intensified sensations of tightness, pressure, or heaviness felt across the chest, neck, or jaw.

Overdose is primarily classified by its potential for life-threatening vasospastic reactions. Regulatory documents explicitly note the risk of severe cerebrovascular events, such as stroke or cerebral hemorrhage, and serious cardiac rhythm disturbances, including ventricular tachycardia and ventricular fibrillation. Furthermore, the potential for Serotonin Syndrome is a severe outcome listed, particularly when Sumatriptan is used with certain antidepressants.

In the event of a confirmed or suspected overdose, individuals must seek immediate medical attention or contact emergency services immediately, even if no symptoms are readily apparent. Regulatory guidance mandates that because no specific antidote is known, the required management must be entirely symptomatic and supportive. Following an overdose event, continuous clinical monitoring or observation is required for a minimum of 12 hours to manage the manifestations and ensure patient stability, as dialysis is of unknown benefit.

Therapeutic Uses of Sumatriptan

What Sumatriptan Treats: Main Uses and Benefits

Sumatriptan is commonly used for the acute treatment of primary headache disorders, including migraine attacks (with or without aura) and the extremely painful episodes characteristic of cluster headaches. It is applied in clinical settings that involve acute or unstable symptom patterns to address the overall symptom load and distress associated with the debilitating head pain.

The medication is relevant in conditions characterized by periods of heightened symptoms, specifically the moderate-to-severe throbbing or pulsating nature of the pain. It also helps address symptom clusters that may become intense, such as significant nausea, vomiting, and significant sensitivity to light (photophobia) and sound (phonophobia), which often occur together during an acute episode.

The use is relevant for easing symptoms and distress. Applied during phases where the patient experiences heightened discomfort, this support helps ease the overall symptom load, may assist with maintaining functional stability, and helps improve day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Severe Episodic Head Pain | Sumatriptan is commonly used to help with moderate-to-severe pain and associated sensory intolerances, supporting improved day-to-day comfort during symptomatic periods.

Regulatory References

  1. National Institutes of Health (NIH) StatPearls overview

Eligibility and Restrictions for Use

The official regulatory profile for Sumatriptan strictly defines who is eligible for treatment, primarily permitting use in adults with a confirmed diagnosis of migraine or cluster headache (for the subcutaneous form). This eligibility is heavily constrained by mandatory exclusions and restrictions documented in government prescribing information (FDA, EMA).

Contraindicated Populations (Absolute Non-Eligibility)

Sumatriptan is contraindicated in patients with a history of Ischemic Heart Disease (including angina or history of myocardial infarction) or Coronary Artery Vasospasm (Prinzmetal's angina). Use is also prohibited in patients with uncontrolled hypertension, Severe Hepatic Impairment, or a history of Stroke or Transient Ischemic Attack (TIA). Furthermore, the medicine is contraindicated in those with Wolff-Parkinson-White syndrome or other accessory conduction pathway disorders.

Age-Related and Concurrent Use Restrictions

Eligibility Category Regulatory Status
Children under 12 Not Recommended; Safety and efficacy are not established.
Older Adults (over 65) Use is Not Recommended due to limited data and increased cardiovascular risk.
Pregnancy/Lactation Restricted; Use must be conditional. Avoid breastfeeding for 12 hours after administration.

Use is also contraindicated within 24 hours of taking another triptan or an ergotamine-containing medication, and within two weeks of stopping a MAO-A inhibitor. Individuals with mild to moderate hepatic impairment require caution and may be restricted to lower maximum doses.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify several substance categories based on the risk of significant pharmacokinetic or pharmacodynamic interactions with Sumatriptan.

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase A Inhibitors (MAO-AIs) is formally contraindicated. This is due to the inhibition of MAO-A, which drastically reduces Sumatriptan clearance and leads to officially documented increased plasma concentrations (exposure). A mandatory separation period requires that Sumatriptan must not be administered within two weeks (14 days) of stopping an MAO-A inhibitor.

Similarly, co-administration with Ergotamine-containing and Ergot-type medications, as well as other Triptans (5-HT1 Agonists), is contraindicated. This restriction is imposed due to the official risk of additive vasospasm (prolonged blood vessel constriction). These substances must be separated from Sumatriptan administration by a minimum of 24 hours.

Other Documented Pharmacodynamic Interactions

Co-use with other serotonergic medicines, including Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), or the herbal supplement St. John's Wort, carries the documented risk of Serotonin Syndrome. This is a pharmacodynamic interaction resulting from the additive effect on the body's serotonin system.

Exposure Notes

In patients with mild-to-moderate hepatic impairment, Sumatriptan clearance is reduced, which results in officially documented increased plasma exposure.

Mechanism of Action

Sumatriptan's mechanism involves a precise, dual pharmacological action mediated by selective activation of specific serotonin receptor subtypes.

Vascular Tone Normalization

This domain focuses on the drug's effect on blood vessel structure and function. Sumatriptan acts as a highly selective agonist at the 5-HT 1B receptors located on the smooth muscle cells of extracerebral cranial arteries. Activation of these receptors causes a reversal of the previously elevated smooth muscle tone in the vessels, leading to selective vasoconstriction.

Suppression of Neurogenic Inflammation

This distinct domain targets the nervous system's involvement in the neurovascular cascade. Sumatriptan concurrently activates the 5-HT 1D receptors found on the terminals of the trigeminal nerve. This neuronal activation inhibits the release of vasoactive pro-inflammatory neuropeptides like CGRP, leading to the modulation of the chemical component of neurogenic inflammation and peripheral sensitization. This dual action modulates the neurovascular cascade.

Dosage and Administration Information

Sumatriptan is an acute treatment administered via three primary routes: the oral tablet, subcutaneous injection, or intranasal spray/powder. All formulations are intended for as-needed use at the onset of the acute attack and are not indicated for prophylactic (preventive) therapy. Oral tablets may be taken with or without food, but must be swallowed whole to ensure proper delivery.

The official dosing schedule varies by route and indication. For oral tablets used in acute migraine, the standard single dose ranges from 25 mg to 100 mg. If the migraine partially resolves or recurs, a second oral dose may be taken after at least 2 hours, with the maximum cumulative dose restricted to 200 mg in any 24-hour period.

For subcutaneous injection, the standard single dose is 6 mg for both acute migraine and cluster headache. If symptoms recur, a second injection may be administered after a minimum interval of 1 hour, with a maximum cumulative dose of 12 mg over 24 hours. This subcutaneous form is distinct, as it is the only route approved for cluster headache. For specific patients with mild to moderate hepatic impairment, the maximum single oral dose should not exceed 50 mg. Furthermore, the safety of treating an average of more than four headaches in a 30-day period has not been established for any formulation.

Recent Clinical Evidence

Evidence for Acute Migraine Attacks

Research for the acute treatment of migraine attacks centers on large Randomized Controlled Trials (RCTs) and meta-analyses exploring how symptoms change over time in primarily adult populations. Studies evaluated various formulations (oral, nasal, injection) and focused on outcomes related to physical discomfort. These included measuring pain-free status at two hours post-administration and sustained pain-free status over 24 hours. Research also measured the evolution of associated symptoms like nausea and light sensitivity. Combined evidence reports that the most consistently measured outcomes related to pain status apply to adult populations.


Evidence for Acute Cluster Headaches

The evidence base for acute cluster headaches relies on focused Randomized Controlled Trials using crossover designs, relevant for assessing short-term symptom patterns in adults. Due to the condition's rapid nature, the trials monitor very short-term outcomes, such as achieving headache response or pain-free status within 15 to 30 minutes. Research explored the consistency of outcomes measured across multiple separate attacks, often monitoring individuals already on stable preventive medication regimens. Most research focused on the rapid-acting subcutaneous and intranasal forms.


Research Gaps, Special Populations, and Follow-up

Research has explored the use in pediatric and adolescent groups, though measured outcomes were less consistently established than for adults. Long-term observational studies track administration patterns over one to two years, but long-term effects are not fully established by the core efficacy trials. The available evidence differs across studies when examining individuals with specific health conditions, as primary efficacy trials often limited the inclusion of these individuals. Consequently, data for certain comorbidity groups remain insufficient in the core randomized research.

Key Studies & References

  1. PROPOSAL FOR THE ADDITION TO THE WHO MODEL LIST OF ESSENTIAL MEDICINES OF SUBCUTANEOUS SUMATRIPTAN FOR THE ACUTE TREATMENT AND V (WHO EML Document)
  2. Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents (Clinical Trial NCT00963937)

Frequently Asked Questions (FAQ)

Common questions about Sumatriptan (FAQ)


Q: How quickly is Sumatriptan expected to start working after use?

Studies on the oral tablet form show that effectiveness is typically measured starting at two hours post-dose. The medicine reaches its highest concentration in the bloodstream around 2 to 2.5 hours. Formulations designed for rapid absorption, such as the injection or nasal spray, may have a faster expected response time.


Q: How long does the effect of Sumatriptan typically last?

Official pharmacology data indicates that the drug has an elimination half-life of approximately 2.5 hours for the oral tablet. Clinical studies, however, track the maintenance of the pain response and overall effect for up to 24 hours following administration.


Q: Does Sumatriptan affect alertness or ability to drive?

Regulatory documents list dizziness and drowsiness as common side effects. Because these effects, or the headache itself, can impact alertness, labeling indicates that individuals should refrain from operating machinery or driving until they feel fully alert.


Q: Is it true that Sumatriptan can raise blood pressure?

Official warnings state that Sumatriptan can cause a transient increase in blood pressure. In rare cases, this has led to significant elevations, including a hypertensive crisis. For this reason, the drug is formally contraindicated for use by patients with uncontrolled high blood pressure.


Q: Is it safe to use Sumatriptan multiple days in a row?

The safety and effectiveness of treating more than an average of four headache attacks in a 30-day period has not been established in clinical trials. Furthermore, official warnings state that using the medicine ten or more days per month is associated with the risk of developing Medication Overuse Headache (MOH).


Q: Do the side effects of Sumatriptan go away quickly?

Common side effects, such as flushing, dizziness, and mild pressure sensations, are generally described in regulatory information as transient or short-lived. If severe or intense symptoms continue or worsen, these symptoms warrant consultation with a healthcare professional.


Q: Are there any specific dietary restrictions to be aware of when using Sumatriptan?

Official prescribing information states that the oral tablet may be taken with or without food, and no specific food restrictions are commonly noted in regulatory documents. However, official guidance describes alcohol as a common headache trigger that some health authorities mention should be avoided during an acute attack.


Q: Is Sumatriptan available as a generic medicine?

Yes, Sumatriptan is widely available as a generic medicine for the oral tablet and nasal spray formulations. The original brand-name version is no longer protected by patent exclusivity, allowing for generic equivalents to be produced.


Q: Why might Sumatriptan not work for some people with the treated condition?

Clinical trial data indicates that the medicine is not effective for every person. Studies show that between 50% and 60% of patients achieved a headache response at two hours post-dose, meaning a significant portion of the studied population did not respond to the treatment.


Q: What are the signs of an allergic reaction to Sumatriptan?

Regulatory labels contain warnings for rare but serious hypersensitivity reactions (allergic reactions), including anaphylaxis. Signs of a severe reaction can include swelling of the face, tongue, or throat, or difficulty breathing, and are officially designated as conditions that require immediate emergency medical assessment.


Q: Does Sumatriptan have any noted effect on mood or anxiety?

Official adverse reaction reports do not typically list general changes in mood or anxiety as a common side effect. However, agitation is listed as one of the key symptoms of the serious, rare condition known as Serotonin Syndrome.


Q: Is Sumatriptan available over the counter in some countries?

In major regulatory markets, including the U.S. and the U.K., Sumatriptan is classified as a prescription-only medication (POM). This status is primarily due to the drug's cardiovascular safety restrictions, not due to abuse potential.


Q: How does Sumatriptan interact with medications containing tramadol?

Official drug interaction data indicates that co-use with medications containing tramadol is a documented concern. This is because both medicines affect the body's serotonin levels, which increases the documented risk of developing Serotonin Syndrome.


Q: What should be done if Sumatriptan causes severe dizziness?

If a person experiences dizziness that is unusually severe or intense, official patient information describes that individuals should refrain from driving or operating machinery. Severe, sudden, or unusual symptoms are documented as needing immediate assessment by a healthcare professional.


Q: Is there a risk of dependence or addiction with Sumatriptan use?

Sumatriptan is not classified as a controlled substance by regulatory bodies, and official documentation indicates that it carries no known risk of drug dependence or addiction. The restrictions on its use are related to potential cardiovascular events and medication overuse headache.


Q: What is the official guidance on consuming alcohol when using Sumatriptan?

Regulatory guidance suggests that consuming alcohol does not change how the drug works in the body. However, as alcohol is a common trigger for severe headaches in some people, many health authorities advise against consuming it during an acute attack.


Q: Can Sumatriptan cause vision changes?

Although uncommon, official regulatory documents have reported adverse reactions involving transient vision loss, decreased vision, and changes in color vision linked to the use of triptans. Changes in vision are described as warranting consultation with a healthcare professional.

How should Sumatriptan be stored and disposed of?

Storage Requirements

Sumatriptan, in all its forms, must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), according to regulatory labeling. The medicine must be kept in its closed container and protected from freezing, excessive heat, moisture, and direct light. For safety, all formulations must be kept out of the reach and sight of children.

Disposal Instructions

Outdated or unused sumatriptan must be disposed of in accordance with local and state regulations. Patients should consult a pharmacist or healthcare professional for guidance. Used injection components (needles and autoinjectors) are classified as sharps and must be placed immediately into an FDA-cleared sharps disposal container; they should not be thrown into the household trash or flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sumatriptan found in:

A-Z Index: